Mineralys Therapeutics Inc (MLYS) delivered better-than-expected financial results for the third quarter of fiscal 2025. The company reported an earnings per share (EPS) of $-0.52, surpassing Wall Street's consensus estimate of $-0.63 by $0.11. Revenue remained at $0.0B, aligning with expectations.
The results highlight the company's operational performance amid its focus on developing treatments for conditions driven by elevated aldosterone levels. Mineralys is a clinical-stage biopharmaceutical company based in Radnor, Pennsylvania, specializing in therapies for hypertension, chronic kidney disease, and obstructive sleep apnea.
Mineralys is advancing its lead product candidate, lorundrostat, a selective aldosterone synthase inhibitor designed to manage cardiorenal conditions. The company has successfully completed the Target-HTN trial, a Phase II proof-of-concept study for lorundrostat in treating uncontrolled and resistant hypertension.
Management will host an earnings conference call to discuss these results and provide further insights into business performance.
This update provides insight into Mineralys Therapeutics Inc's financial health, reflecting its ability to exceed analyst expectations. Investors are encouraged to review the full earnings release and listen to management's commentary for a comprehensive understanding of the quarter's performance and future outlook.